Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00424606
Status:
COMPLETED
Last Update Posted:
2015-05-20
First Post:
2007-01-18
Brief Title:
Epirubicin and Docetaxel Combination ET or Epirubicin Followed by Docetaxel ET for Node Negative N0 High Risk Breast Cancer Patients
Sponsor:
Hellenic Oncology Research Group
Organization:
Hellenic Oncology Research Group
Study Overview
Official Title:
A Multicenter Randomized Phase III Study of Adjuvant Treatment With Epirubicin Followed by Docetaxel ET Versus Epirubicin and Docetaxel Combination ET in High Risk Lymph Node Negative Breast Cancer Patients
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The combination of taxanes and especially docetaxel with an anthracycline seems to be an important part of the chemotherapy regimens used in the adjuvant setting of patients with early-stage node-positive breast cancer patients Whether sequential or concurrent administration of these drugs is preferable is not yet known especially in patients with node-negative high risk tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None